Evidence map›Paper›PMID 27630014›Full record

Trial reportBMC psychiatry2016

The synchronized trial on expectant mothers with depressive symptoms by omega-3 PUFAs (SYNCHRO): Study protocol for a randomized controlled trial.

Daisuke Nishi, Kuan-Pin Su, Kentaro Usuda, Yi-Ju Jill Chiang, Tai-Wei Guu, Kei Hamazaki, Naoki Nakaya, Toshimasa Sone, Yo Sano, Yoshiyuki Tachibana and 5 more

Registry-linked trialOpen access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in BMC psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02166424 (The Synchronized Trial on Expectant Mothers With Depressive Symptoms by Omega-3 PUFAs), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02166424 phase3completednot on this map

The Synchronized Trial on Expectant Mothers With Depressive Symptoms by Omega-3 PUFAs (SYNCHRO)

TypeinterventionalSponsorTokyo Medical UniversityRan2014 to 2017Enrolled108ConditionsPregnancy, DepressionArmsOmega-3 polyunsaturated fatty acids, Olive oil
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Omega-3 fatty acid addition during pregnancy.The Cochrane database of systematic reviews · 2018
    Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 2 countries.

Daisuke NishiDepartment of Obstetrics and Gynecology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan. d-nishi@umin.ac.jp.ORCID 0000-0001-9349-3294
Kuan-Pin SuDepartment of Psychiatry & Mind-Body Interface Laboratory (MBI-Lab), China Medical University Hospital, No. 2, Yuh-Der Road, Taichung, 404, Taiwan. cobolsu@gmail.com.
Kentaro UsudaDepartment of Obstetrics and Gynecology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
Yi-Ju Jill ChiangDepartment of Psychiatry & Mind-Body Interface Laboratory (MBI-Lab), China Medical University Hospital, No. 2, Yuh-Der Road, Taichung, 404, Taiwan.
Tai-Wei GuuDepartment of Psychiatry & Mind-Body Interface Laboratory (MBI-Lab), China Medical University Hospital, No. 2, Yuh-Der Road, Taichung, 404, Taiwan.
Kei HamazakiDepartment of Public Health, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama, 930-0194, Japan.
Naoki NakayaDepartment of Preventive Medicine and Epidemiology, Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8573, Japan.
Toshimasa SoneDepartment of Rehabilitation, Faculty of Health Science, Tohoku Fukushi University, 6-149-1 Kunimigaoka, Aoba-ku, Sendai, Miyagi, 989-3201, Japan.
Yo SanoToda Chuo Women's Hospital, 2-26-3 Kamitoda, Toda, Saitama, 335-0022, Japan.
Yoshiyuki TachibanaDivision of Infant and Toddler Mental Health, Department of Psychosocial Medicine, National Center for Child Health and Development, 2-10-1 Ookura, Setagaya-ku, Tokyo, 157-8535, Japan.
Hiroe ItoDepartment of Obstetrics and Gynecology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
Keiich IsakaDepartment of Obstetrics and Gynecology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
Kenji HashimotoDivision of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba, 260-8670, Japan.
Tomohito HamazakiDepartment of Medicine, Toyama Jonan Onsen Daini Hospital, 1-13-6, Taromarunishimachi, Toyama, Toyama, 939-8271, Japan.
Yutaka J MatsuokaDepartment of Obstetrics and Gynecology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
Tokyo Medical University · JPChina Medical University · TWCenter for Forensic Mental Health, Chiba University · JPNational Center For Child Health and Development · JPTohoku Fukushi University · JPTohoku University · JPTowada City Hospital · JPUniversity of Toyama · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMaternal depression can be harmful to both mothers and their children. Omega-3 polyunsaturated fatty acid (PUFA) supplementation has been investigated as an alternative intervention for pregnant women with depressive symptoms because of the supporting evidence from clinical trials in major depression, the safety advantage, and its anti-inflammatory and neuroplasticity effects. This study examines the efficacy of omega-3 PUFA supplementation for pregnant women with depressive symptoms in Taiwan and Japan, to provide evidence available for Asia. The rationale and protocol of this trial are reported here.

methodsThe Synchronized Trial on Expectant Mothers with Depressive Symptoms by Omega-3 PUFAs (SYNCHRO) is a multicenter, double-blind, parallel group, randomized controlled trial. Participants will be randomized to either the omega-3 PUFAs arm (1,200 mg eicosapentaenoic acid and 600 mg docosahexaenoic acid daily) or placebo arm. Primary outcome is total score on the Hamilton Rating Scale for Depression (HAMD) at 12 weeks after the start of the intervention. We will randomize 56 participants to have 90 % power to detect a 4.7-point difference in mean HAMD scores with omega-3 PUFAs compared with placebo. Because seafood consumption varies across countries and this may have a major effect on the efficacy of omega-3 PUFA supplementation, 56 participants will be recruited at each site in Taiwan and Japan, for a total number of 112 participants. Secondary outcomes include depressive symptoms at 1 month after childbirth, diagnosis of major depressive disorder, changes in omega-3 PUFAs concentrations and levels of biomarkers at baseline and at 12 weeks' follow-up, and standard obstetric outcomes. Data analyses will be by intention to treat. The trial was started in June 2014 and is scheduled to end in February 2018. DISCUSSION: The trial is expected to provide evidence that can contribute to promoting mental health among mothers and children in Asian populations.

trial registrationClinicaltrials.gov: NCT02166424 . Registered 15 June 2014; University Hospital Medical Information Network (UMIN) Center: UMIN000017979. Registered 20 May 2015.

Indexed as

Research DesignAdultChildDepressive DisorderDietary SupplementsDouble-Blind MethodFatty Acids, Omega-3FemaleHumansJapanMothersPregnancyPregnancy ComplicationsTaiwanTreatment OutcomeFatty Acids, Omega-3DepressionEicosapentaenoic acidOmega-3 polyunsaturated fatty acidsPregnancyPrevention

Identifiers

PMID27630014
PMCPMC5024529
OpenAlexW2519653941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.